Back to search results

CRN09682 for SST2-Expressing Neuroendocrine Neoplasms and Other Solid Tumors

This study is testing a new drug called CRN09682 for people with certain types of cancer, including neuroendocrine neoplasms (NENs) and other solid tumors that have a specific marker called SST2. The main goals are to see how safe CRN09682 is, how well people tolerate it, and if it shows any signs of shrinking tumors. Researchers will start by giving different doses to find the safest and most effective amount. To join, you need to have a confirmed diagnosis of metastatic or locally advanced cancer that has progressed, and your tumor must show the SST2 marker. The study is currently recruiting about 150 participants.

Study design
This is a Phase 1/2, multicenter, open-label study. It aims to enroll about 150 participants to evaluate the safety and effectiveness of CRN09682.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for side effects from the first dose of CRN09682 until 30 days after their last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07129252

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Crinetics Pharmaceuticals Inc.
~150 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:CRN09682

At a glance

Recruiting sites
27 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
(Dose Escalation) Incidence and severity of DLTs.
Measured over From first dose through Day 21.
+3 more outcomes measured

Conditions

SST2-positive Neuroendocrine Neoplasms
Neuroendocrine Tumors
Neuroendocrine Neoplasm

Explore related trials

Neuroendocrine CarcinomaNeuroendocrine NeoplasmSolid NeoplasmSSTR2 Gene

Where it's being run

27 sites across 15 states
California4
Spain4
Texas3
Colorado2
Michigan2
Pennsylvania2
Virginia2
Arizona1

Who to contact

Contact if you are a potential participant or caregiver
[email protected]
833-827-9741
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.
Have one or more measurable disease location per RECIST version 1.1.
Have a tumor that expresses SSR confirmed by SSR imaging.
Have an ECOG performance status of 0, 1, or 2.

Exclusion

Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.
Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.
Use of anticancer agents within specified intervals prior to the first dose of study drug.
Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.
Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
Participants with carcinoid syndrome.
Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.
Have prior treatment with MMAE.
Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.

What this trial measures

  • (Dose Escalation) Incidence and severity of DLTs.From first dose through Day 21.
  • (Dose Escalation) Incidence and severity of AEs and SAEs at each dose level and incidence of AEs leading to discontinuation from study drug.From first dose of study drug to 30 days after the last dose.
  • (Dose Expansion) Nature, incidence, and severity of AEs and SAEs at the Expansion Dose.From first dose of study drug to 30 days after the last dose.
  • (Dose Expansion) Interruptions at the Expansion Dose.At Day 1 of each cycle through study completion, approximately 2 years.